RxDoctor Payments Data

Michael McMullen, MD

Ophthalmology · Orangeburg, SCNPI 1235450628

Payments from drug & device makers

$3,686in general payments, 2019–2025

Across 164 payments — averaging $22.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alcon$715
  • NEW World Medical,inc.$326
  • Biotissue Holdings Inc.$261
  • Amgen$218
  • Johnson & Johnson$218
  • plus $928 from 17 others

What the payments were for

  • Food & beverage$3,686100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,686 in reported general payments places this provider in the 60th percentile of 293 ophthalmology providers in South Carolina.

See all ophthalmology providers in South Carolina

Medicare billing

Part B allowed, 2024
$294,553
Medicare patients
1,101
Services billed
2,467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost138$52,925
RhopressaNetarsudil Mesylate92$45,877
Latanoprost1,845$18,371
CombiganBrimonidine Tartrate/Timolol31$13,629
RocklatanNetarsudil Mesylat/Latanoprost32$13,530
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat570$12,016
SimbrinzaBrinzolamide/Brimonidine Tart42$10,656
Travoprost63$8,346
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol63$8,143
Dorzolamide Hcl302$7,765
Prednisolone Acetate157$5,357
Alphagan PBrimonidine Tartrate15$4,969
Brimonidine Tartrate291$3,923
MoxifloxacinMoxifloxacin Hcl99$2,814
Timolol Maleate250$2,562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$1,018$71,523184 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$143$59,407124 claims
AlconSimbrinza$715$10,65642 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 293 ophthalmology providers in South Carolina.

Other ophthalmology in Orangeburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →